|
Medtronic submits this report to comply with fda regulations 21 cfr parts 4 and 803.Medtronic has made reasonable efforts to provide as much relevant information as is available to the company as of the submission date of this report.This report does not constitute an admission or a conclusion by fda, medtronic, or its employees that the device, medtronic, or its employee caused or contributed to the event described in the report.Medtronic will submit a supplemental report if additional relevant information becomes known.
|
|
It was reported that a patient implanted with a 25mm mosaic aortic valve is being evaluated for a transcatheter valve-in-valve replacement.The reason for evaluation was not reported.No intervention or patient complications have been reported as a result of this event.Subsequently, 17 days later, a transcatheter valve was implanted valve-in-valve.The reason for intervention was reported as aortic stenosis (as).No additional adverse patient effects were reported.
|